Story

Novacyt Revenue Jumps 18% in First Half on Strong Diagnostics Demand

ENTHMSVIIDZHZH-TWJAKOHI
Jul 28, 20261 min read
Novacyt Revenue Jumps 18% in First Half on Strong Diagnostics Demand

Summary

The molecular diagnostics firm reported H1 2026 revenue of £11.6 million, lifted by strong growth in its instrumentation and clinical segments and a recent acquisition.

Text size
Background

Molecular diagnostics company Novacyt reported first-half 2026 revenue of £11.6 million, an 18% increase compared to the same period in the prior year. The France-based firm attributed the growth to strong performance across its key business segments and expanded regional sales.

Key Growth Drivers

The company's instrumentation segment was a significant contributor, recording approximately 30% year-over-year growth. Novacyt credited this performance to the market adoption of its LightBench Discover platform.

The clinical segment also delivered robust results, with revenue growing more than 20%. This was supported by demand for its non-invasive prenatal testing technology and sales of products related to sickle cell disease. Additionally, the acquisition of Southern Cross Diagnostics in March contributed £1.8 million to revenue in the post-acquisition period.

Sample IUX Markets – In-articleAd

Regional Performance and Outlook

Novacyt saw notable growth in key international markets. Revenue from the Americas rose by over 30%, while the Asia-Pacific region saw an increase of about 22%. The company stated that instrument sales and demand for reproductive health products drove performance in both regions.

Looking ahead, Novacyt is conducting a restructuring program that it expects will deliver up to £4.0 million in annualized cost savings. The company also anticipates receiving IVDR accreditation for its DPYD kit in the coming months.

Read next

More on Stocks
Back to latest news

LATEST